Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1667 | Thyroid (non-cancer) | ICEECE2012

Resistance to thyroid hormone: clinical, biochemical and genetic features of Mediterranean population

Amor A. , Oriola J. , Quiros C. , Alfayate R. , Borras V. , Escribano A. , Gonzalez C. , Gutierrez A. , Mauri M. , Perez P. , Pico A. , Vourliotaki I. , Halperin I.

Introduction: Resistance to thyroid hormones (RTH) is a genetic disorder caused in 85% of cases by mutations in thyroid hormone receptor beta gene (TRĪ²). The current information about it in Spanish population is scarce, limited to case reports or short series of patients. Thus, we aimed to describe the clinical, biochemical and genetic features of Mediterranean patients with RTH referred to our institution (one of the referral centres in Spain) for genetic testing during ...

ea0026p258 | Pituitary | ECE2011

Prevalence of germline mutations of AIP gene in sporadic aggressive somatotropinomas

Puig-Domingo M , Oriola J , Halperin I , Mora M , Diaz-Soto G , Perales M J , Alvarez-Escola C , Lucas-Morante T , Bernabeu Ignacio , Marazuela Monica

Most kindreds of familial isolated pituitary adenomas (FIPA) with mutated AIP develop somatotropinomas, characterized by an aggressive clinical phenotype including early age at diagnosis, large tumours and frequent invasiveness. In non-family cases, the prevalence of AIP mutations in pituitary adenomas is lower than 10%. There is no information of AIP prevalence in isolated somatotropinomas characterized by poor response to conventional treatment.Aim: To...

ea0029p1825 | Thyroid cancer | ICEECE2012

Prognostic markers in Papillary Thyroid Cancer by immunohistochemistry

Castelblanco E. , Gallel P. , Martinez M. , Barrera L. , Capel I. , Moreno P. , Gimenez G. , Puig-Domingo M. , Bella R. , Porta M. , Halperin I. , Lopez S. , Orellana R. , Cameselle J. , Matias-Guiu X. , Mauricio D. , Robledo M. , Maravall J.

Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study...